TCGX · TCGX Acquisition Corp.
Price & Indicators
The closing range uses available history since Aug 5, 2026; less than a full year is stored.
Up next
Metrics snapshot
Useful current figures from the complete screener profile.
Equibles Rating
blended score · not investment adviceBlended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Technicals
trend & momentum for long-term holders SellIllustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
KPI extraction has been attempted, but no publishable series is available from the examined filings. This is not evidence that the company reports no KPIs.
Versus peers
Shell Companies — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
TCGX
this stock
TCGX Acquisition Corp.
|
$113.26M | — | — | — | 0.5% |
|
VYLR
Vylor Inc.
|
$48.31B | — | — | — | — |
|
CLUS
Cluster Group Holdings Ltd Co
|
$8.00B | — | — | — | — |
|
DMII
Drugs Made In America Acquisition II Corp.
|
$648.15M | +2.9% | — | — | 0.2% |
|
EVAC
EQV Ventures Acquisition Corp. II
|
$603.18M | +2.9% | — | — | 0.0% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every section- Filed
- Oct 19, 2026
- This year
- 6
TCGX Acquisition Corp. entered a Business Combination Agreement on October 18, 2026 with TriGemX Bio, Inc. (formerly Kallyope) to merge at a $361,000,000 pre-money equity value, with a $160,000,000 PIPE Financing, expected to close in Q1 2027.
ViewPerformance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| TCGX | -19.0% | -31.7% | — | -20.0% | — |
| SPY | -1.2% | -0.6% | +8.1% | +0.8% | +12.8% |
| vs SPY | -17.9% | -31.1% | — | -20.8% | — |